Biotechnology and nanotechnology

Filter results by

Search Help
Currently selected filters that can be removed

Keyword(s)

Type

2 facets displayed. 0 facets selected.

Geography

2 facets displayed. 0 facets selected.
Sort Help
entries

Results

All (47)

All (47) (0 to 10 of 47 results)

  • Table: 27-10-0266-01
    Frequency: Every 2 years
    Description: Biotechnology use and development survey, indicators for innovative biotechnology firms by firms size for Canada, biennial survey from 1999 to 2005.
    Release date: 2008-09-26

  • Table: 27-10-0267-01
    Frequency: Every 2 years
    Description: Biotechnology use and development survey, indicators for innovative biotechnology firms by sector, for Canada, biennial survey from 1999 to 2005.
    Release date: 2008-09-26

  • Table: 27-10-0268-01
    Frequency: Every 2 years
    Description: Biotechnology use and development survey, indicators for innovative biotechnology firms for Canada and by region , biennial survey from 1999 to 2005.
    Release date: 2008-09-26

  • Articles and reports: 88F0006X2007006
    Description:

    This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

    Release date: 2007-12-05

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210324
    Geography: Canada
    Description:

    Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210326
    Geography: Canada
    Description:

    Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.

    Release date: 2007-10-09

  • Articles and reports: 88F0006X2007005
    Description:

    This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

    Release date: 2007-08-31

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10
Data (3)

Data (3) ((3 results))

Analysis (44)

Analysis (44) (0 to 10 of 44 results)

  • Articles and reports: 88F0006X2007006
    Description:

    This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

    Release date: 2007-12-05

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210324
    Geography: Canada
    Description:

    Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210326
    Geography: Canada
    Description:

    Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.

    Release date: 2007-10-09

  • Articles and reports: 88F0006X2007005
    Description:

    This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

    Release date: 2007-08-31

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88-003-X20050028021
    Geography: Canada
    Description:

    Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

    Release date: 2005-06-20

  • Articles and reports: 88F0006X2005010
    Description:

    This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.

    Release date: 2005-04-29

  • Articles and reports: 88F0006X2005009
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.

    Release date: 2005-04-27
Reference (0)

Reference (0) (0 results)

No content available at this time.

Date modified: